Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abhijit Ray

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
Bioorganic & Medicinal Chemistry|April 3, 2003
5H-Dibenzo[c,h]1,6-naphthyridin-6-ones: novel topoisomerase I-targeting anticancer agents with potent cytotoxic activityAlexander L Ruchelman, Sudhir K Singh, Abhijit Ray, et al.
Oncotarget|September 9, 2017
A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumorsAdam L Cohen, Abhijit Ray, Matthew Van Brocklin, et al.
Bioorganic & Medicinal Chemistry Letters|January 15, 2013
Synthesis and evaluation of 4,5-dihydro-5-methylisoxazolin-5-carboxamide derivatives as VLA-4 antagonistsAjay Soni, Abdul Rehman, Keshav Naik, et al.
European Journal of Pharmacology|February 26, 2009
RBx 6198: a novel alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasiaKamna Nanda, Krishna S Naruganahalli, Suman Gupta, et al.
International Immunopharmacology|January 23, 2010
Pharmacological profile of AW-814141, a novel, potent, selective and orally active inhibitor of p38 MAP kinasePuneet Chopra, Onkar Kulkarni, Shashank Gupta, et al.
European Journal of Pharmacology|May 4, 2013
RBx10080307, a dual EGFR/IGF-1R inhibitor for anticancer therapyRuchi Tandon, V Senthil, D Nithya, et al.
Clinical Breast Cancer|June 6, 2017
A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast CancerTheresa L Werner, Abhijit Ray, John G Lamb, et al.
Bioorganic & Medicinal Chemistry Letters|August 2, 2005
Synthesis and SAR of novel oxazolidinones: discovery of ranbezolidBiswajit Das, Sonali Rudra, Ajay Yadav, et al.
Oncotarget|July 9, 2016
A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanomaAbhijit Ray, Matthew A Williams, Stephanie M Meek, et al.
European Journal of Pharmacology|March 5, 2011
Pharmacodynamic and pharmacokinetic profile of RBx 343E48F0: a novel, long acting muscarinic receptor antagonistSuman Gupta, Shivani Malhotra, Sandeep Sinha, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Bioorganic & Medicinal Chemistry|April 3, 2003
5H-Dibenzo[c,h]1,6-naphthyridin-6-ones: novel topoisomerase I-targeting anticancer agents with potent cytotoxic activityAlexander L Ruchelman, Sudhir K Singh, Abhijit Ray, et al.
Oncotarget|September 9, 2017
A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumorsAdam L Cohen, Abhijit Ray, Matthew Van Brocklin, et al.
Bioorganic & Medicinal Chemistry Letters|January 15, 2013
Synthesis and evaluation of 4,5-dihydro-5-methylisoxazolin-5-carboxamide derivatives as VLA-4 antagonistsAjay Soni, Abdul Rehman, Keshav Naik, et al.
European Journal of Pharmacology|February 26, 2009
RBx 6198: a novel alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasiaKamna Nanda, Krishna S Naruganahalli, Suman Gupta, et al.
International Immunopharmacology|January 23, 2010
Pharmacological profile of AW-814141, a novel, potent, selective and orally active inhibitor of p38 MAP kinasePuneet Chopra, Onkar Kulkarni, Shashank Gupta, et al.
European Journal of Pharmacology|May 4, 2013
RBx10080307, a dual EGFR/IGF-1R inhibitor for anticancer therapyRuchi Tandon, V Senthil, D Nithya, et al.
Clinical Breast Cancer|June 6, 2017
A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast CancerTheresa L Werner, Abhijit Ray, John G Lamb, et al.
Bioorganic & Medicinal Chemistry Letters|August 2, 2005
Synthesis and SAR of novel oxazolidinones: discovery of ranbezolidBiswajit Das, Sonali Rudra, Ajay Yadav, et al.
Oncotarget|July 9, 2016
A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanomaAbhijit Ray, Matthew A Williams, Stephanie M Meek, et al.
European Journal of Pharmacology|March 5, 2011
Pharmacodynamic and pharmacokinetic profile of RBx 343E48F0: a novel, long acting muscarinic receptor antagonistSuman Gupta, Shivani Malhotra, Sandeep Sinha, et al.
Pageof 11